Wu, D., Wang, Y., Chen, S., Li, Y., Huang, R., Wei, X., Mi, R., Sun, M., Li, Y., Huang, H., Luo, Y., Liu, B., He, P., Li, D., Zhu, X., Li, F., Ren, J., Ge, J., Liu, Z., Jiang, S., Zhu, X., Hu, W., Wang, W., Gong, Y., Yin, J., Patel, P., Xu, X., Lv, M., Wang, Y. (2025). Phase 1/2, multi-center, open-label clinical study to evaluate the safety, pharmacokinetics, and efficacy of zefamenib in patients with relapsed/refractory acute leukemia. Blood. https://doi.org/10.1182/blood-2025-5209